Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Safello Announces Partnership with Crypto Tax Service Provider Divly

Stockholm, 14 March 2022 | Sweden’s leading crypto broker Safello  today announced it is launching a partnership with tax service provider Divly , to offer its users a seamless process to calculate taxes and handle tax reports in relation to their cryptocurrency transactions. The integration with Divly makes the tax declaration process easy and convenient for users by providing them with a tool to obtain income statements and also fulfills Safello’s commitment to increase the percentage of people who declare tax on their crypto transactions, which

Implantica presents at Aktiedagen Stockholm on March 15 at 18:30

Implantica AG (publ), a med-tech company providing smart medical implants using advanced eHealth technology at the forefront of the upcoming eHealth revolution, announces today that its founder and CEO, Peter Forsell, is presenting virtually in Swedish at Aktiespararna’s event Aktiedagen Stockholm on Tuesday, March 15 at 18:30 CET.In his presentation, Peter Forsell shares the latest news regarding Implantica’s RefluxStop™, the CE marked product that has all the attributes to become the new standard of care to treat acid reflux, a treatment field affecting 17% of the EU and 19% of the US

Episealer® (knee) to be presented at the British knee congress

Episurf Medical (Nasdaq: EPIS B) today announces that the Episealer® Knee technology is presented at the UK Biological Knee Society’s Annual Meeting 2022 (Peckforton Castle, Cheshire, March 15-16),  as a part of the scientific program. The presentation is held by Mr Paul Jermin from Robert Jones & Agnes Hunt Orthopaedic Hospital NHS Foundation Trust, Oswestry, United Kingdom, and focuses on surgical technology and clinical results from the use of the Episealer® Knee implant. “As the orthopaedic community once again gathers for important physical meetings, we are pleased to see that the

Atlas Copco to acquire Lewa and Geveke

Nacka, Sweden, March 14, 2022: Atlas Copco has agreed to acquire LEWA GmbH and subsidiaries, and Geveke B.V. and subsidiaries for a combined enterprise value of MEUR 670 (BSEK 7.15). LEWA is a leading manufacturer of diaphragm metering pumps, process pumps and complete metering systems.  Geveke distributes compressors and engineers advanced and complex process pump installations.LEWA was founded in 1952 and is based in Germany. The company has around 1200 employees and in 2021 they had revenues of MEUR 233 (BSEK 2.4). LEWA offers industry-specific high-quality pump solutions for a wide

Bawat Presents At Several Investor Events This Week

Stockholm, Sweden, March 14th, 2022: Bawat Water Technologies AB (“Bawat” or the “Company”) a Danish maritime Greentech engineering company presents a number of investor events during the last week of the subscription period which runs until Thursday March 17.   · Aktiespararna’s Aktiedagen, March 14 at 6.30pm to 7.00pm (in English). Follow the event online, or reserve a seat at Aktiespararna’s website      · HC Andersen Capital – Bawat Webinar, March 15 at 1.00pm (in Danish). The presentation is

Lynparza approved in US for early breast cancer

14 March 2022 07:05 GMT Lynparza approved in the US as adjuvant treatment for patients withgermline BRCA-mutated HER2-negative high-risk early breast cancer First and only approved medicine targeting BRCA mutations in early breast cancer New data show Lynparza demonstrated overall survival benefit in early breast cancer AstraZeneca and MSD's Lynparza (olaparib) has been approved in the US for the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after

Update on US review of Fasenra in nasal polyps

14 March 2022 07:00 GMT Update on US regulatory review of Fasenrain chronic rhinosinusitis with nasal polyps The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for Fasenra (benralizumab) for patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). The sBLA submitted to the FDA by AstraZeneca included data from the OSTRO Phase III trial, which met both co-primary endpoints with a safety profile consistent with the known profile of the medicine.[1] The

Kemira increases prices for AKD based products in the APAC region

Kemira Oyj, Press Release, March 14, 2022 at 9.00 a.m. (EET)Kemira increases prices for AKD based products in the APAC region Kemira will implement a price increase of 10-30% for selected AKD (alkyl ketene dimer) wax based sizing products in APAC. The price adjustment will be effective immediately or as the existing AKD contracts allow. The decision is triggered by continuous cost increases of main raw materials, energy, logistics and HSE regulatory compliance requirements. AKD wax is the main raw material for AKD sizing products. Kemira remains committed to mitigating the impact of

Aker Offshore Wind and Mainstream Renewable Power Close Transaction for Offshore Wind Development in Japan

With reference to the stock exchange notice on 12 August 2021, Aker Offshore Wind and Mainstream Renewable Power (“Mainstream”) have closed the transaction which will see them take an initial 50 percent ownership stake in Progression Energy’s 800 MW floating offshore wind project in Japan. The project is a well-formed early-stage development opportunity, and the site has been identified as ideal for floating wind.With the successful closing of the transaction, the parties will now collectively continue to mature the project. As a consortium, the three companies bring together highly

Faron Publishes Research From INTEREST Trial

Faron Pharmaceuticals Ltd (“Faron” or “Company”)     Faron Publishes Research Identifying Gene Mutation in Interferon Receptor that Contributes to Corticosteroid Response and Outcome in ARDS and COVID-19 Patients   · Single nucleotide polymorphism identified during analysis of data from Phase III INTEREST trial of Traumakine · Gene mutation in interferon alpha/beta receptor (IFNAR2) is associated with better outcomes among intravenous interferon beta-1a treated ARDS patients, irrespective of prior treatment with glucocorticosteroids · Analysis of COVID-19 Host

Subscription price for Moberg Pharma's warrants of series 2020:1 determined

STOCKHOLM, March 14[th], 2022. Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") hereby announces that the subscription price for warrants of series 2020:1 is SEK 6.47. The exercise period begins on 16 March 2022 and runs until 29 March 2022. The last day for trading in warrants of series 2020:1 on Nasdaq Stockholm is 25 March 2022.In 2020, Moberg Pharma carried out a rights issue of units. Each unit consisted of one (1) ordinary share and one (1) warrant in Moberg Pharma. Two (2) warrants entitle the holder to subscribe for one (1) new ordinary share in Moberg Pharma. The

Son André Hval Appointed Group Director Commercial Letting at Heimstaden

Heimstaden strengthens the management team by hiring Son André Hval as Group Director Commercial Letting. He will start in his new role during the spring.Heimstaden is a leading residential real estate company in Europe, with appr. 150,000 homes in ten countries. Heimstaden has today a portfolio of over 900,000 square meters commercial space, accounting for appr. seven percent of the total rental income in the company. "Although residential rental housing is our primary business area, we have a large portfolio of commercial premises around Europe. We are delighted to have Son André on

Mycronic receives order for an SLX mask writer

Mycronic AB (publ) has received an order for an SLX mask writer from an existing customer in Asia. The order value is in the range of USD 4-6 million. Delivery of the system is planned for the third quarter of 2022.The SLX laser mask writer meets rising demand for photomasks for the semiconductor industry and a future need for replacement and modernization. Photomasks manufactured by laser mask writers are of high importance and account for 70-75 percent of all photomasks produced for semiconductor manufacturing. SLX is a new and modern mask writer based on the same technology as Mycronic’s

Stayble Therapeutics comments the ongoing study in Russia

Stayble Therapeutics AB comments on the Company's ongoing clinical phase IIb study, which is ongoing in Russia, among other places. The company follows the development closely and our current assessment is that the study can continue without risking patient safety, quality or implementation. This means that the Company continues to follow the previously communicated timelines.Since 2020, Stayble has been conducting a phase IIb study with the aim of developing STA363 as a new standard treatment for patients suffering from degenerative disc disease. The study is designed as a multicenter

CEO, CFO and Board member increases shareholding in Scout Gaming

Scout Gaming has been informed that the CEO, CFO and one Board member have increased their shareholding during Friday March 11[th].Andreas Ternström acquired 14.000 shares and has a total holding of 473,340, Niklas Jönsson acquired 31.000 shares and has a total holding of 43,500 and a member of Board acquired 34.850 shares. For further information, please contact:Andreas Ternstrom, CEOTel: +46 706 770 660Email: andreas.ternstrom@scoutgaminggroup.com Niklas Jönsson, CFOTel: +46 725 494 173Email: niklas.jonsson@scoutgaminggroup.com About Scout Gaming GroupScout Gaming

Phase 1 First Gas

14 March 2022 IOG plc Phase 1 First Gas IOG plc ("IOG", or "the Company"), (AIM: IOG.L), the Net Zero UK gas and infrastructure operator focused on high return projects, is pleased to confirm First Gas from Phase 1 of its Saturn Banks Project. IOG has released a new video to mark this milestone: https://youtu.be/kZBzzm01M8g.  Andrew Hockey, CEO of IOG, commented: "I am delighted to confirm that Saturn Banks Phase 1 First Gas has been achieved. Yesterday the Blythe well was safely opened up and IOG gas has started to be delivered into Bacton and on into the UK market. The

Cloetta´s Annual Report 2021 available on the website

Cloetta´s Annual Report 2021 has today been published on Cloetta´s website.The Annual Report, which also includes the sustainability report, is available on www.cloetta.com in pdf-format as well as summarized in a separate digital version. The Annual Report is also available on the Group’s website in European Single Electronic Format (ESEF). The Annual Report includes Cloetta´s first reporting in accordance with the EU Taxonomy regulation, a framework established to facilitate sustainable investments. This information is information that Cloetta AB (publ) is obliged to make public

Diakrit and Virtuance join forces to deliver a new standard in real estate marketing, backed by Adelis as their international growth partner

Diakrit, the leader in digital property marketing content, has partnered with Adelis Equity Partners (“Adelis”) to accelerate the company’s international growth. As a first step, Virtuance, Diakrit’s main counterpart in the US market, has joined the group, creating an even stronger global leader with a best-in-class offering across three continents. Management and founders will continue to hold a significant ownership, together with Adelis.With over 20 years of global experience, Diakrit helps leading real estate brokerages across the world successfully win more business and grow their

Expansion of Everest Medicine’s licence agreement to include South Korea

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the company has expanded its licensing agreement with Everest Medicines II Limited (HKG: 1952) (“Everest”) to extend the territory covered to include South Korea.“We continue to have a fruitful and positive collaboration with Everest and are delighted that we have come to an agreement also around South Korea,” said CEO Renée Aguiar-Lucander. The extension results in an upfront payment of USD 3 million to Calliditas as well as additional payments and royalties related to future potential

Realheart hires investment advisor in the UAE

Press release, March 14, 2022 Realheart has partnered with an experienced investment advisor in the UAE, Dr Abdulla Khalfan Saeed Alkindi, who will help the company meet the high level of interest in the product and the company in the Middle East.Realheart, who is developing the world's first four-chamber artificial heart, has received considerable international attention. There is particularly strong interest in the Middle East. This is partly due to the attention given to the inventor and founder of Realheart, Azad Najar, who himself was born and raised in Iraqi Kurdistan. Another

Kesko’s sales grew in February

Kesko Group's sales totalled €852.1 million in February 2022, representing an increase of 6.8% on the previous year. In comparable terms, sales grew by 6.9%.“Kesko’s sales grew in February in both the grocery trade division and the building and technical trade division. Sales for the building and technical trade division grew by 18% in comparable terms, thanks to growth in B2B trade. Sales for the grocery trade division grew by 4.5%,” says Mikko Helander, Kesko’s President and CEO. Sales in the grocery trade division totalled €442.3 million in February, an increase of 4.5%. Grocery sales

InDex Pharmaceuticals prepares for commercialisation of cobitolimod

March 13, 2022 – InDex Pharmaceuticals Holding AB (publ) is planning for self-commercialisation of the drug candidate cobitolimod in the US with strategic collaborations in other regions. Launch is expected in 2027, with the potential for annual sales to reach more than USD 1 billion, in moderate to severe left-sided ulcerative colitis. An in-depth presentation of the strategy and market potential, together with the execution of the phase III study CONCLUDE with cobitolimod will be provided at InDex’s Capital Markets Day, tomorrow March 14, 15.00-17.00 CET.Approximately 400,000 patients

Raising Voices exhibition in The Catalyst will help inform change

An exhibition of creative work which aims to tell the stories of people living in poverty and hardship in Stoke-on-Trent is taking place at Staffordshire University this month.An exhibition of creative work which aims to tell the stories of people living in poverty and hardship in Stoke-on-Trent is taking place at Staffordshire University this month. The Raising Voices exhibition and Manifesto for Change event will take place at The Catalyst building on Leek Road on Thursday 24 March starting at 6pm. The University has been commissioned by Stoke-on-Trent’s Hardship Commission to

The Olkiluoto 3 EPR plant unit’s electricity production has started

The electricity production of Olkiluoto’s third nuclear power plant unit started today on Saturday, 12 March 2022, at 12.01 p.m. Olkiluoto 3 EPR (OL3) significantly increases domestic electricity production.The startup of OL3’s reactor took place on 21 December 2021, after which the power output has been gradually increased to approximately 27 percent. Today on Saturday, 12 March 2022, at 12.01 p.m., the plant unit has been connected to the national grid at a power output of 103 MW. The moment was long-awaited; OL3 significantly improves Finland’s electricity self-sufficiency and helps in

There are no items matching the current filter
There are no more items matching the current filter
Back to top